Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Summit Securities Limited - Updates

2018-07-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUMMITSEC 533306

0
PSEi jumps as investors pick up large-cap issues

2018-07-11 bworldonline
THE MAIN INDEX jumped on Wednesday on selective buying of large-cap firms, as most investors remained on the sidelines due to lack of new leads.
SUMMITSEC 533306 SMIVY PSKXF SVTMF AYAAY PHSXY SM PSE ALI AYAAF

7
DM Wenceslao slumps in market debut

2018-06-29 bworldonline
PROPERTY developer and construction firm D.M. Wenceslao & Associates, Inc. raised P8.15 billion in the country’s first initial public offering (IPO) this year, but its shares closed below its offering price on its first day of trading.
SUMMITSEC 533306 PSKXF PHSXY PSE

2
Summit Securities Limited - Financial Result Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUMMITSEC 533306

2
Summit Securities Limited - Outcome of Board Meeting

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUMMITSEC 533306

7
Stocks rise on strong Q1 economic growth data

2018-05-10 bworldonline
LOCAL EQUITIES firmed up on Thursday, albeit with minimal gains, following the release of first-quarter economic growth figures that stayed within market expectations.
SUMMITSEC 533306 PSKXF PHSXY PSE

2
Stocks mixed as PSEi rebounds from weeklong losses

2018-05-04 bworldonline
SHARE prices were mixed in thin trading, with the benchmark index rising after a string of post-holiday losses as investors were enticed by the market’s oversold conditions, though most individual stocks closed lower.
SUMMITSEC 533306

2
Stocks rebound on ‘thin market’

2018-05-04 bworldonline
Local stocks bounced back on the end of the trading week, following its poor performance Thursday, May 3, as the market went under “oversold condition.”
SUMMITSEC 533306

7
PSE index rallies above 7,700 level

2018-04-27 bworldonline
LOCAL stocks continued to rally on Friday, closing above the 7,700 level, as investors kept an eye on the historic meeting between the leaders of North and South Korea.
SUMMITSEC 533306 PSKXF PHSXY PSE

7
PSEi drops further on lingering overseas concerns

2018-04-17 bworldonline
THE MAIN INDEX suffered another sell-off on Tuesday, weighed down by lingering concerns on the tensions surrounding the United States and Russia.
SUMMITSEC 533306 PSKXF PHSXY PSE

7
Stocks slide further on rising US-Russia tensions

2018-04-17 bworldonline
The main index suffered another sell-off on Tuesday, April 17, weighed down by lingering concerns on the tensions surrounding the United States and Russia.
SUMMITSEC 533306 PSKXF PHSXY PSE

2
Summit Securities Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUMMITSEC 533306

2
Summit Securities Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUMMITSEC 533306

2
Summit Securities Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUMMITSEC 533306

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...